Massoud Marcel, Koscielny Serge, Lapusan Simona, Bosq Jacques, Ribrag Vincent
Departement de Medecine, Institut Gustave Roussy, Villejuif, France.
Leuk Lymphoma. 2008 Aug;49(8):1510-5. doi: 10.1080/10428190802203788.
We retrospectively reviewed 105 cases of primary mediastinal large B-cell lymphoma (PMLBL). Patients were treated with dose-intensified chemotherapy according to the GELA protocols without planned radiotherapy. Radiotherapy was delivered to patients with a lymphoma proven sensitive to CHOP who could receive irradiation for localised disease. Seventy-six patients achieved a complete remission (24%) or unconfirmed CR (49%), and 15 (14%), a partial remission. Patients treated with intensified induction therapy had a better FFP rate than patients treated with CHOP chemotherapy even when radiotherapy was restricted to partial responders to the dose-intensified chemotherapy regimen (p = 0.01). In the multivariate analysis for overall survival, a poor performance status and CHOP chemotherapy remained associated with a poor outcome (p = 0.02 and 0.02, respectively). Radiotherapy might not be necessary in PMLBL when a CR or a Cru is achieved with dose-intensified chemotherapy. CHOP chemotherapy yield inferior results compared to dose-intensified chemotherapy with more frequent progression on therapy.
我们回顾性分析了105例原发性纵隔大B细胞淋巴瘤(PMLBL)患者。患者根据GELA方案接受剂量强化化疗,未进行计划性放疗。对于经证实对CHOP敏感且可接受局部疾病照射的淋巴瘤患者进行放疗。76例患者达到完全缓解(24%)或未确认的完全缓解(49%),15例(14%)为部分缓解。即使放疗仅限于剂量强化化疗方案的部分缓解者,接受强化诱导治疗的患者的无进展生存率也高于接受CHOP化疗的患者(p = 0.01)。在总生存的多因素分析中,较差的体能状态和CHOP化疗仍然与不良预后相关(分别为p = 0.02和0.02)。当通过剂量强化化疗实现完全缓解或未确认的完全缓解时,PMLBL可能无需放疗。与剂量强化化疗相比,CHOP化疗效果较差,治疗期间进展更频繁。